AI in Diagnostics Market Size Overview

The global AI in diagnostics market was estimated at US$ 1.12 billion in 2023 and is projected to grow to US$ 12.65 billion by 2034, rising at a compound annual growth rate (CAGR) of 24.64% from 2024 to 2034. The demand for AI in diagnostic testing has increased significantly due to the various benefits AI provides. One of the major benefits is reduced human error, which improves overall diagnostic results that can be used by professionals to develop appropriate treatment options.

The integration of artificial intelligence (AI) in the diagnostics market is revolutionizing the way healthcare professionals interpret medical data, enhance diagnostic accuracy, and improve patient outcomes. Among the leading companies pioneering these innovations are GE Healthcare, Paige, and a host of other trailblazers. Below is an overview of recent developments from some of the top players in the AI in diagnostics market.

GE Healthcare: Enhancing Ultrasound Capabilities

Headquarters: Illinois, U.S., North America
Recent Development: In July 2024, GE HealthCare announced a significant acquisition, agreeing to purchase the clinical AI software business of Intelligent Ultrasound Group PLC for an estimated value of $51 million. This strategic move is aimed at bolstering GE Healthcare’s portfolio in integrated AI-driven image analysis solutions. Intelligent Ultrasound is recognized for its innovative technology that enhances the intelligence and efficiency of ultrasound procedures, thus paving the way for improved diagnostic capabilities.

Paige: Pioneering Molecular Biomarker Identification

Headquarters: Los Angeles, U.S., North America
Recent Development: In August 2024, the AI startup Paige launched a groundbreaking offering in the realm of cancer diagnostics. The New York City-based company introduced OmniScreen, a biomarker module that utilizes AI to identify an impressive 1,228 molecular biomarkers from conventional pathology slides. This new product not only evaluates over 505 genes but does so using Hematoxylin and eosin (H&E) stains, providing pathologists with the capability to assess digital images of stained cancer tissue slides effectively. The innovation signifies a leap forward in the precision and efficiency of cancer diagnostics, offering valuable insights that can guide treatment decisions.

Download Statistics: https://www.towardshealthcare.com/price/5244

Other Noteworthy Players in the AI Diagnostics Space

In addition to GE Healthcare and Paige, several other companies are making significant contributions to the AI in diagnostics landscape:

• Niramai: This Indian startup employs thermal imaging and AI to detect early-stage breast cancer, providing a non-invasive alternative to traditional mammography.
• Imagen Technologies: Focused on enhancing radiology, Imagen uses AI to streamline image interpretation, thereby improving diagnostic accuracy and efficiency.
• AliveCor Inc.: Known for its AI-powered ECG technology, AliveCor enables patients to monitor their heart health through personal devices, providing real-time insights to both patients and healthcare providers.
• Digital Diagnostics, Inc.: This company leverages AI to enhance diagnostic processes, particularly in dermatology, by providing accurate skin cancer assessments.
• Qure AI: With a focus on radiology, Qure AI develops algorithms that assist radiologists in interpreting chest X-rays, significantly reducing the time taken for diagnoses.
• Aidoc: Known for its advanced imaging AI solutions, Aidoc supports radiologists by prioritizing critical cases and flagging abnormalities in real time.

The AI in diagnostics market is rapidly evolving, driven by technological advancements and the commitment of key players to improve healthcare outcomes. Companies like GE Healthcare and Paige are leading the way with innovative solutions that enhance diagnostic capabilities and efficiency. As these technologies continue to develop, they promise to reshape the future of healthcare, making diagnoses more accurate, timely, and accessible for patients worldwide. The advancements in AI diagnostics represent a significant step forward in the pursuit of personalized and precision medicine, ultimately leading to better health outcomes for patients.

AI in Diagnostics Market: Accuracy & Efficiency

Artificial intelligence (AI) has become a significant part of healthcare and is being used in almost all sectors, including diagnostics. The integration of AI has increased the growth and development of the healthcare industry. In diagnostic testing, AI is used to analyze medical images (CT scans, X-rays, ultrasounds, MRIs, and DXAs), large patient data, vital signs (pulse rate, body temperature, blood pressure, and respiration rate), medical history, and laboratory test results. AI provides several advantages in diagnostics, such as accuracy, efficiency, reduced human errors, and cost savings. Healthcare professionals can make more informed decisions and develop personalized treatment options. The AI in the diagnostics market is growing due to reduced healthcare costs, reduced healthcare burden on professionals, and enhanced patient satisfaction.

For instance,

• In September 2024, in order to extend and enhance its products that utilize artificial intelligence to assist in identifying illnesses, the Indian firm Qure.AI secured $65 million from investors led by Lightspeed Venture Partners and 360 ONE Asset Management.
• In February 2024, the novel AI cancer early detection method from the All India Institute of Medical Science was announced. Under the Ministry of Electronics and Information Technology, the AI system was developed in collaboration with the Centre for Development of Advanced Computing in Pune. It is powered by deep learning models that enable it to analyze complicated medical data with “unprecedented accuracy and efficiency.” It was trained on 500,000 radiological and histological pictures from 1,500 patients of the two most frequent cancer types, ovarian and breast.

Please feel free to contact at sales@towardshealthcare.com